Abstract: An aqueous cleaning composition comprising: (a) from 0.01 to 0.5% by weight of the composition of a grease loosening system comprising: i) 50% or more by weight of the system of a low emulsifying surfactant wherein the low emulsifying surfactant is a nonionic ethoxylate having an HLB value of from about 13 to about 20; and ii) 50% or less by weight of the system of a high emulsifying material wherein the high emulsifying material is selected from the group consisting of nonionic surfactant having an HLB value of less than 13, a surfactant other than nonionic surfactants; antimicrobial quats and mixtures thereof; (b) a shine polymer comprising at least one monomer comprising a substantially planar 5-7 membered ring, said monomer preferably being selected from the group consisting of vinylpyrrolidone, vinylimidazoline, maleimide, styrene sulfonate and vinylcaprolactam; and (c) optionally a non-quaternary ammonium compound antimicrobial agent.

Abstract: A cleaning agent composition for use in removal of a polysiloxane adhesive remaining on a substrate, the composition containing a tetrahydrocarbylammonium fluoride and an organic solvent, wherein the organic solvent contains an alkylene glycol dialkyl ether and a lactam compound represented by formula (1). (in formula (1), R101 represents a C1 to C6 alkyl group, and R102 represents a C1 to C6 alkylene group.

Abstract: The present invention relates to copolymer formulations of poly(itaconic acid-co-2-acrylamido-2-methylpropane sulfonic acid) for dishwasher detergent compositions with a controlled amount of a second polymeric component.

Abstract: Fabric care compositions that include perfume encapsulates and a quaternary ammonium ester compound, where the shell of the encapsulates include an acrylate or methacrylate material. Related methods of using and making such compositions.

Abstract: Described herein is a system, methods, processes and nutrient-rich products-by-process, which are generated by the conversion of winery derivatives into nutrient-rich products in an ecological manner. Integration of this system into a winery assists the winery to manage its previously-considered waste nutrient-rich products in an ecological manner, which can also optionally provide them with a novel revenue stream. The system, methods, and processes are used to convert winemaking derivatives into bioactive nutrient-rich products comprising antioxidants and other bioactive molecules that reside within the marc and lees. These nutrient-rich products can be used as natural flavour, texture and color enhancers, in addition to nutritional ingredients to fortify processed foods and consumer recipes. They can also be used as health supplements and in the cosmetic industry.

Abstract: System for maturation of wine comprises a tank and one or more wooden barrels and flow connectors to allow circulation of maturing wine between the tank and the one or more barrels. The barrels may comprise a wooden exterior and an internal volume and a plurality of internal wooden surfaces extending inwardly of the wooden exterior into the internal volume to increase wood surface area. The barrel may be a traditional oak barrel.

Abstract: A bioreactor including a containment structure containing a liquid culture medium for cultivating seaweed. The containment structure includes a sidewall extending vertically between a top and bottom section where the bottom section has an effluent arranged to allow extraction of cultivated seaweed. A spiral liner is positioned adjacent to an inside surface of the sidewall. The recirculator includes a pump arranged to continuously receive a portion of the liquid culture medium via an inlet from the bottom section and output the liquid culture medium via the outlet at the top section. Sensors monitor environmental conditions within the bioreactor. Light emitters are arranged along a surface of the spiral liner. Flow generators, positioned within the containment structure in a spiral configuration between the top section and bottom section, are configured to direct a flow of the liquid culture medium from the top section toward the bottom section of the containment structure.

Abstract: Provided is a culture chamber that includes a plurality of recesses each formed of a bottom portion and an opening portion. The bottom portion has a hemispherical shape or a truncated cone shape. The opening portion is defined by a wall that surrounds an area from a boundary between the opening portion and the bottom portion to an end of each of the recesses, the wall having a taper angle in a range from 1 to 20 degrees. An equivalent diameter of the boundary is from 50 ?m to 2 mm and a depth from a bottom of the bottom portion to the end of each of the recesses is from 0.6 or more times to 3 or less times the equivalent diameter, and the wall defining the opening portion forms a surface continuous to the bottom portion. An inclination of the continuous surface changes at the boundary.

Abstract: A cell culture apparatus includes a cell culture module including multiple cell culture chambers. A manifold connects the multiple cell culture chambers together along a side of the cell culture module. The manifold includes a side wall base structure connected to the side of the cell culture module and a column structure that is formed as a monolithic part of the side wall base structure. The column structure defines a fluid flow pathway through the manifold and to inlets to the cell culture chambers to allow filling and emptying of the cell culture chambers of liquid medium.

Abstract: A biocompatible column for concurrent micro-positron emission tomography (micro-PET) or micro-single photon emission computed tomography (micro-SPECT) of at least two cell cultures is provided, the column having an inlet, an axially oriented perfusion chamber and an outlet, wherein the perfusion chamber includes a porous solid phase with sponges having biopolymer (such as silk, silk fibroin, collagen, gelatin, agarose, alginate, polylactic acid, agar, or methyl-cellulose), an aqueous liquid phase, a first cell culture and a second cell culture, wherein the first cell culture and the second cell culture are in contact with the solid phase and wherein the first cell culture is separated from the second cell culture by the solid phase. Also provided is a method and a kit for concurrent micro-PET or micro-SPECT of at least two cell cultures.

Abstract: Biocompatible, mechanically-dynamic thermoresponsive devices, methods for forming the devices, and exemplary applications for the devices are described. The devices include a series of wells therein and provide for temperature-controlled mechanostimulation of single cells or groups of cells that can be retained in the wells of a device. Mechanostimulation can be single instance of any duration, continuous, or regular or irregular cyclic mechanostimulation of single cells, cell clusters, cell spheroids, or organoids and may be utilized in any of a variety of biomedical applications including, without limitation, cellular engineering, cellular phenotyping, and drug discovery/screening.

Abstract: The invention relates to a comparison unit (130) configured for determining if a first pH measuring device of a first tank (104; 106) is affected by a pH-measuring problem, the comparison unit being configured for: receiving a first CO2 concentration and a first pH value, the first CO2 concentration being a CO2 concentration of a first gas volume above a medium in a first tank, the first CO2 concentration and the first pH value being measured at a first time when the medium in the first tank is in pH-CO2 equilibrium state with the first gas volume and before said equilibrium state is modified by the metabolism of a cell culture in the first tank, the first pH value being a measured value provided by a first pH measuring device operatively coupled to the first tank (102); receiving a second CO2 concentration and a second pH value, the second CO2 concentration being a CO2 concentration of a second gas volume above a medium in a second tank, the second CO2 concentration and the second pH value being measured

Abstract: Techniques are described for automated microinjection of substances, such as genetic material, into single cells in tissue samples. An example system comprises a robotic manipulator apparatus configured to hold and position a micropipette. Furthermore, the system comprises a microscope camera positioned to observe an injection site. A computing device receives image data from a microscope camera of the system, where the image data represents an image of a tissue sample. The computing device receives, via a user interface, an indication of a line traced by a user on the image of a tissue sample. In response, the computing device controls the robotic manipulator apparatus to move a tip of the micropipette along a path defined by the trajectory line. The pressure controller injects a gas into the micropipette to eject a substance out of the micropipette at one or more points along the path defined by the trajectory line.

Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. The methods may comprise gene-editing at least a portion of the TILs to enhance their therapeutic efficacy. Such TILs find use in therapeutic treatment regimens.

Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR expression and methods of using these splice-switching oligonucleotides to treat cancer, specifically castrate resistant prostate cancer.

Abstract: A method includes containing an algae media within a contactor, introducing a stream of natural gas comprising up to 80 wt % carbon dioxide (CO2) into the contactor, contacting the natural gas on the algae media and thereby allowing the algae media to consume CO2 from the natural gas, and discharging a stream of natural gas comprising 2 wt % or less CO2 from the contactor.

Abstract: The present invention provides an improved method of utilizing agricultural waste and fungal mycelium in order to create mycelium-based biocomposite materials capable of serving in structural, load-bearing capacities. The dramatic reduction in the embodied carbon of a part grown with the method of the present invention over prior art creates benefit for the use of mycelium-based biocomposites in a new, regenerative economy. The present invention creates parts of superior strength over prior art using far less embodied carbon in the process of manufacture.

Abstract: Provided is a fermentation fungal substance of Astragalus membranaceus/Paecilomyces cicadae and its use. The fermentation fungal substance is obtained by solid fermentation with Astragalus membranaceus powder as a fermentation substrate and Paecilomyces cicadae as a fermentation strain. The fermentation fungal substance of Astragalus membranaceus/Paecilomyces cicadae in the present disclosure plays a significant role in treating hyperuricemia and/or hypertriglyceridemia.

Abstract: The present disclosure relates to a method for pretreating an evaporator for accelerating odor reproduction of an odor reproduction device for a vehicle air conditioning system, and a method for pretreating an evaporator surface of the present disclosure may include: a step of preparing an inoculation of malodorous microorganisms; a step of preparing and pretreating an evaporator; and a step of immobilizing malodorous microorganisms on an evaporator surface.

Abstract: A method of dissociating single cells from a biological tissue sample is described herein, along with systems for performing such methods. The method includes generating one or more ultrasonic wave pulses using a transducer comprising one or more Fresnel Annular Sector Actuator (FASA) elements; and applying energy from the generated one or more ultrasonic wave pulses to a sample container holding the biological tissue sample through a coupling medium that couples the one or more FASA elements to the sample container to dissociate single cells from the biological tissue is described herein.

Abstract: Methods and systems and related compositions for separating through a solid matrix a mixture comprising a nucleic acid in a concentration of 1 ?M or less, together with a target compound having a water solubility equal to or greater than 0.001 g per 100 mL, which can be used for managing fluid flow, biochemical reactions and purification of the nucleic acid or other target analytes. The method comprises contacting the solid matrix with a target compound removing agent having a water solubility equal to or less than 0.05 g per 100 mL at 25° C. at 1 atm pressure with water having a solubility in the removing agent of less than 10 g per 100 mL at 25° C. at 1 atm pressure, the contacting performed to remove the target compound from the solid matrix.

Abstract: Aspects of the disclosure relate to liquid chromatography (e.g., HPLC) methods which enable high resolution separations of polynucleotides of various lengths, sequences, and/or base compositions in a highly tunable manner. In some embodiments, the disclosure describes liquid chromatographic methods for separating a nucleic acid (e.g., a polyadenylated nucleic acid, such as an mRNA) from a complex mixture by using multiple ion pairing agents in the same mobile phase system. Accordingly, in some embodiments methods described by the disclosure are useful for assessing the quality of pharmaceutical preparations comprising nucleic acids.

Abstract: The invention provides for systems, methods, and compositions for targeting and editing nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a DNA-targeting Cpf1 protein, at least one guide molecule, and at least one adenosine deaminase protein or catalytic domain thereof.

Abstract: The disclosure relates to methods for the screening, identification, and/or application of one or more microorganisms of use in imparting one or more beneficial properties to one or more plants.

Abstract: The application discloses multimeric assemblies packaging one or more active component and their use to carry out nucleic acid regulation or gene editing.

Abstract: Aspects of the invention relate to antisense oligonucleotides directed to the interleukin 17 receptor (IL-17R), and other targets. Spherical nucleic acid formulations or compositions of antisense oligonucleotides and related methods of treatment are also provided.

Abstract: The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the complement factor C3 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of a C3 gene and to treat subjects having a complement component C3-associated disease, e.g., paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), atypical hemolytic uremic syndrome (aHUS), neuromyelitis optica (NMO), multifocal motor neuropathy (MMN), myasthenia gravis (MG), and C3 glomerulonephritis.

Abstract: The invention relates to nucleic acid molecules for pseudouridylation of a target uridine in a target RNA in a mammalian cell, wherein the nucleic acid molecule comprises a guide region capable of forming a partially double stranded nucleic acid complex with the target RNA comprising the target uridine, wherein the partially double stranded nucleic acid complex is capable of engaging a mammalian pseudouridylation enzyme, wherein the guide region assists in positioning the target uridine in the partially double stranded nucleic acid complex for it to be converted to a pseudouridine by the mammalian pseudouridylation enzyme.

Abstract: The present disclosure provides a method for knocking out an N-myristoyltransferase (NMT) gene from Eimeria tenella, and belongs to the technical field of microorganisms. The method includes: mixing sporozoites of Eimeria tenella with a pCRISPR::EtNMT plasmid and a pEtNMT::DHFR plasmid, and subjecting a resulting mixture to electrotransformation to obtain NMT gene-knockout Eimeria tenella. The method provided by the present disclosure can successfully knock out the NMT gene from Eimeria tenella, which lays a foundation for studying the function of the Eimeria tenella gene and developing a vaccine therefor.

Abstract: A method of treating a subject suffering from cancer comprising a step of administering an effective amount of a group of double-stranded RNA molecules to the subject, wherein the RNA molecule is isolated or derived from a bacteria of the genus Escherichia. A method of inhibiting growth or proliferation of cancer cells comprising a step of contacting said cells with said RNA molecule; and a pharmaceutical composition for treating cancer comprising said RNA molecule and a pharmaceutically tolerable excipient. Also a double-stranded RNA molecule and a recombinant vector comprising the double-stranded RNA molecule.

Abstract: Disclosed is an oligonucleotide or a pharmacologically acceptable salt thereof, wherein the oligonucleotide comprises at least one defined nucleoside structure, can bind to a human nSR100 gene and has human nSR100 expression inhibiting activity. The oligonucleotide has a length of 12 to 20 mer, and is complementary to a defined target region. Further, disclosed is an nSR100 gene expression inhibitor and a cancer therapeutic agent containing the oligonucleotide or the pharmacologically acceptable salt thereof. The cancer therapeutic agent is used for treatment of small cell lung cancer, prostate cancer, or breast cancer.

Abstract: An antiviral agent is provided, having a phosphorodiamidate morpholino oligomer with an antisense sequence to a portion of a genome of a strain of Zika virus (ZIKV). The antiviral agent finds many uses, such as in a pharmaceutical composition, a method of treating ZIKV-mediated disease, a method of preventing ZIKV-mediated disease, a method of reducing or preventing the replication of ZIKV in a host cell, a method of controlling the spread of ZIKV in donated tissue, a treated tissue sample, and in the manufacture of a medicament for the treatment or prevention or ZIKV-mediated disease.

Abstract: This invention discloses the use of non-coding RNA SNHG17 as a biomarker and a therapeutic target that relates to the technical field of tumor biotherapy. This invention discloses a use of the non-coding RNA SNHG17 for the manufacture of a detection agent for predicting the drug resistance of fulvestrant. This invention also discloses the use of shRNA for inhibiting non-coding RNA SNHG17 expression. This shRNA can knockdown the expression of the non-coding RNA SNHG17 efficiently. In this way, the sensitivity of fulvestrant-resistant breast cancer cells can be increased. So this invention has good prospects for drug development.

Abstract: The disclosure provides for eRNA-targeted transcriptional reprogramming through targeted reduction of eRNAs for a clinically relevant gene, TNFSF10, resulting in a selective control of interferon-induced apoptosis. A method of inhibiting a TNFSF10 gene expression in a human cell is disclosed. The methods described herein comprise contacting the human cell with a single-stranded antisense compound consisting of the sequence selected from a set of SEQ ID NOs: disclosed herein, wherein the antisense compound targets an enhancer RNA (eRNA) transcribed from a genomic enhancer sequence or region. The eRNA is an TNFSF10 eRNA sequence comprising the nucleic acid sequence selected from the SEQ ID NOs disclosed herein which inhibits expression of the TNFSF10 gene in the human cell.

Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.

Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Transmembrane protease, serine 6 (TMPRSS6) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a TMPRSS6 gene and to methods of preventing and treating a TMPRSS6-associated disorder, e.g., a disorder associated with iron overload and/or a disorder of ineffective erythropoiesis, e.g., hereditary hemochromatosis, ?-thalassemia (e.g., ?-thalassemia major and ?-thalassemia intermedia), polycythemia vera, myelodysplastic syndrome, congenital dyserythropoietic anemias, pyruvate kinase deficiency, erythropoietic porphyria, Parkinson's Disease, Alzheimer's Disease or Friedreich's Ataxia.

Abstract: Described are methods for utilizing X-aptamers for detecting human SNAP25 and fragments thereof, and compositions comprising the X-aptamers.

Abstract: The present invention relates to a reporter system for trans-translation based on the reassembly of GFP and on the capacity of tmRNA to add a peptide tag to a protein blocked on a ribosome. The invention also relates to the in vivo or in vitro use of this reporter system for studying trans-translational activity and for identifying compounds capable of inhibiting trans-translation and therefore capable of being of interest as antibiotics.

Abstract: The present disclosure is generally related to compositions and methods for obtaining Bacillus licheniformis cells/strains having increased protein production capabilities. Certain embodiments of the disclosure are related to genetically modified Bacillus licheniformis cells/strains derived from parental B. licheniformis cells/strains comprising a variant rghR2 gene.

Abstract: A promoter operably linked to a gene encoding a protein is disclosed. The promoter drives expression of the protein in a yeast cell in the absence of methanol. Also disclosed are vectors, host cells and expression systems that include the promoter, as well as methods of using the promoter to express proteins in yeast.

Abstract: Disclosed herein are novel Pichia pastoris strains for expression of exogenous proteins with substantially homogeneous N-glycans. The strains are genetically engineered to include a mutant OCH1 allele which is transcribed into an mRNA coding for a mutant OCH1 gene product (i.e., ?-1,6-mannosyltransferase, or “OCH1 protein”). The mutant OCH1 protein contains a catalytic domain substantially identical to that of the wild type OCH1 protein, but lacks an N-terminal sequence necessary to target the OCH1 protein to the Golgi apparatus. The strains disclosed herein are robust, stable, and transformable, and the mutant OCH1 allele and the ability to produce substantially homogeneous N-glycans are maintained for generations after rounds of freezing and thawing and after subsequent transformations.

Abstract: The present invention generally provides methods to generate plants with high frequency of spontaneous haploid genome doubling for use in doubled haploid production. The invention relates to the BUBR1 nucleic acid and protein sequences identified, which are associated with spontaneous haploid genome doubling.

Abstract: Genetically modified plants and methods of detecting diseases by a relevant color change in the genetically modified plant compared to a non-genetically modified plant are provided. Also disclosed is a system for remote detection of pathogens on crops and a methods for treating crops under a pathogenic attack.

Abstract: The invention provides recombinant DNA molecules and constructs, as well as their nucleotide sequences, useful for modulating gene expression in plants. The invention also provides transgenic plants, plant cells, plant parts, and seeds comprising the recombinant DNA molecules operably linked to heterologous transcribable DNA molecules, as are methods of their use.

Abstract: The disclosure relates to precise modifications in wheat plant genomes including the heterologous integration of nucleic acid sequences that include a regulatory element at a predetermined locus. Also provided are wheat cells, wheat plants, wheat seeds, and processed wheat products comprising the modified wheat genomes.

Abstract: The present invention refers to a method for controlling undesired vegetation at a plant cultivation site, the method comprising the steps of providing, at said site, a plant that comprises at least one nucleic acid comprising a nucleotide sequence encoding a wild-type or a mutated protoporphyrinogen oxidase (PPO) which is resistant or tolerant to a PPO-inhibiting herbicide by applying to said site an effective amount of said herbicide. The invention further refers to plants comprising wild-type or mutated PPO enzymes, and methods of obtaining such plants.

Abstract: The invention provides novel recombinant DNA molecules, compositions, and methods for selectively regulating the expression of a transcribable polynucleotide molecule or recombinant protein in a male reproductive tissue of a transgenic plant. The invention also provides transgenic plants, plant cells, plant parts, seeds, and commodity products comprising such DNA molecules and compositions.

Abstract: Disclosed herein are transfection complexes comprising at least one cell surface ligand; at least one helper lipid component; and a transfection enhancer. Also disclosed are pharmaceutical compositions comprising the disclosed transfection complexes, and a pharmaceutically acceptable carrier. Further, disclosed are methods of transfecting a cell, the method comprising the steps of: obtaining a transfection complex as disclosed; and contacting a cell with the transfection complex.

Abstract: The invention relates to adenoviral vectors, cells for use in generating adenoviral vectors, methods for generating adenoviral vectors, and therapeutic uses of adenoviral vectors in gene therapy, tumour therapy and as vaccines.

Abstract: The invention features lentiviral transfer vectors that include heterologous nucleic acids to be introduced into a cell. The lentiviral transfer vector may be characterized by the following features: (a) including a cytomegalovirus (CMV) promoter; (b) including a polynucleotide encoding a partial gag protein that includes a mutated INS1 inhibitory sequence that reduces restriction of nuclear export of RNA; (c) not including a polynucleotide encoding the INS2, INS3, and INS4 inhibitory sequences of gag; (d) not including an SV40 origin of replication and/or an f1 origin of replication; (e) including a cPPT sequence that contains splice site; (f) including an EF1alpha promoter with intact splice donor and acceptor sites; and (g) including hepatitis B PRE with mutation in start codon of X protein ORF.